Phase I trial of CP 4200 for the treatment of myelodysplastic syndromes.
Latest Information Update: 01 Jun 2011
At a glance
- Drugs CP 4200 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 01 Jun 2011 Planned initiation date changed to 1 Dec 2011.
- 21 Oct 2010 This trial is expected to be initiated in the first half of 2011 according to a Clavis Pharma media release.
- 21 Oct 2010 New trial record